The manufacturer was informed of the following event through report (ref.Mw5147012) from fda.On (b)(6) 2017, patient had pre-operative diagnosis: 1- aortic stenosis (severe) 2- lv hypertrophy 3-reduced lv function (ef 50%) 4- renal failure (stage 3) with following operation 1- minimally invasive aortic valve replacement (xl perceval pericardial heart valve) via right anterior mini-thoracotomy 2- rigid titanium plate for third rib fixation.Patient tolerated procedure well.Since patient was diagnosed with severe prostatic aortic valve stenosis, acute on chronic diastolic heart failure, hepatitis c chronic kidney disease stage iii, thrombocytopenia suspected liver cirrhosis, mean aortic gradient of the prostatic valve was 72 mmhg, reintervention (tavr) was performed on 6 july 2021.Mortality score is 14.3% high risk.Operative procedure included urgent transfemoral transcatheter aortic valve replacement with a 26 mm edwards sapient s3 valve, deployment of the s3 valve into the degenerated xl perceval valve central cerebral embolic protection, large sheath 14 french left common femoral artery, pigtail catheter 5 french right common femoral artery, temporary pacemaker access site left common femoral vein, and 6 french sheath per md records.Reportedly, patient tolerated procedure well and was returned to recovery in stable condition.No further information is available at this time.
|